Document Detail


Neuropeptides and diabetic retinopathy.
MedLine Citation:
PMID:  23043302     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Diabetic retinopathy, a common complication of diabetes, develops in 75% of patients with type 1 and 50% of patients with type 2 diabetes, progressing to legal blindness in about 5%. In the recent years, considerable efforts have been put into finding treatments for this condition. It has been discovered that peptidergic mechanisms (neuropeptides and their analogues, activating a diverse array of signal transduction pathways through their multiple receptors) are potentially important for consideration in drug development strategies. A considerable amount of knowledge has been accumulated over the last three decades on human retinal neuropeptides and those elements in the pathomechanisms of diabetic retinopathy which might be related to peptidergic signal transduction. Here, human retinal neuropeptides and their receptors are reviewed, along with the theories relevant to the pathogenesis of diabetic retinopathy both in humans and in experimental models. By collating this information, the curative potential of certain neupeptides and their analogues/antagonists can also be discussed, along with the existing clinical treatments of diabetic retinopathy. The most promising peptidergic pathways for which treatment strategies may be developed at present are stimulation of the somatostatin-related pathway and the pituitary adenylyl cyclase-activating polypeptide-related pathway or inhibition of angiotensinergic mechanisms. These approaches may result in the inhibition of vascular endothelial growth factor production and neuronal apoptosis; therefore, both the optical quality of the image and the processing capability of the neural circuit in the retina may be saved.
Authors:
Robert Gábriel
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't; Review    
Journal Detail:
Title:  British journal of clinical pharmacology     Volume:  75     ISSN:  1365-2125     ISO Abbreviation:  Br J Clin Pharmacol     Publication Date:  2013 May 
Date Detail:
Created Date:  2013-04-08     Completed Date:  2013-10-01     Revised Date:  2014-05-08    
Medline Journal Info:
Nlm Unique ID:  7503323     Medline TA:  Br J Clin Pharmacol     Country:  England    
Other Details:
Languages:  eng     Pagination:  1189-201     Citation Subset:  IM    
Copyright Information:
© 2012 The Author. British Journal of Clinical Pharmacology © 2012 The British Pharmacological Society.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Angiogenesis Inhibitors / therapeutic use
Diabetic Retinopathy / drug therapy*,  metabolism
Humans
Neuropeptides / metabolism*
Pituitary Adenylate Cyclase-Activating Polypeptide / metabolism
Signal Transduction
Somatostatin / metabolism
Chemical
Reg. No./Substance:
0/Angiogenesis Inhibitors; 0/Neuropeptides; 0/Pituitary Adenylate Cyclase-Activating Polypeptide; 51110-01-1/Somatostatin
Comments/Corrections

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  The salmonid myostatin gene family: a novel model for investigating mechanisms that influence duplic...
Next Document:  Solid dispersions: a strategy for poorly aqueous soluble drugs and technology updates.